

Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?

Adeline Dolly* , Jean-François Dumas  & Stéphane Servais* 

INSERM UMR 1069, Nutrition Croissance et Cancer, Université de Tours, Tours, France

Abstract

Research investigators have shown a growing interest in investigating alterations underlying skeletal muscle wasting in patients with cancer. However, skeletal muscle dysfunctions associated with cancer cachexia have mainly been studied in preclinical models. In the present review, we summarize the results of clinical studies in which skeletal muscle biopsies were collected from cachectic vs. non-cachectic cancer patients. Most of these studies suggest the presence of significant physiological alterations in skeletal muscle from cachectic cancer patients. We suggest a hypothesis, which connects structural and metabolic parameters that may, at least in part, be responsible for the skeletal muscle atrophy characteristic of cancer cachexia. Finally, we discuss the importance of a better standardization of the diagnostic criteria for cancer cachexia, as well as the requirement for additional clinical studies to improve the robustness of these conclusions.

Keywords Cancer cachexia; Skeletal muscle alterations; Clinical studies; Myosteatosis; Mitochondria

Received: 23 April 2020; Revised: 24 July 2020; Accepted: 16 September 2020

*Correspondence to: Drs Stéphane Servais and Adeline Dolly, INSERM UMR 1069, Nutrition Croissance et Cancer, Université de Tours, 10, Boulevard Tonnellé, 37032 Tours Cedex 1, France. Phone +33 2 47 36 75 24, Fax +33 2 47 36 62 26, Email: stephane.servais@univ-tours.fr; adlinedolly@outlook.fr

Introduction

Cancer cachexia is a complex multifactorial syndrome characterized by involuntary and pathological weight loss, mainly due to skeletal muscle wasting. Patients experience a deterioration of their nutritional status, which is associated with a profound weakening of the body. Formation of oedemas, loss of appetite (or anorexia), and persistent fatigue are also observed. These effects considerably reduce patients' quality of life and overall survival. Cancer cachexia is a cause of death for 20–25% of patients,¹ and it is also a co-morbidity significantly affecting their overall survival. In 2011, a consensus of international experts defined cancer cachexia as being characterized by a progressive loss of skeletal muscle mass, with or without loss of adipose mass. This cachexia cannot be fully supported by conventional nutritional support and gradually leads to functional impairment.² It has been described as a continuum with three stages of diagnosis: pre-cachexia, cachexia, and refractory cachexia. The risk of

progression depends on the stage and the type of tumour, the presence of systemic inflammation, the response to antitumour treatment, as well as inter-individual variations such as genetic predisposition, body composition, food intake, physical activity, and co-morbidities.^{3,4} It is however important to note that the severity of cachexia does not appear to correlate with the size of the tumour.⁵ The prevalence of cachexia in cancer patients is estimated to be ~35%.⁶ It can even reach ~80–90% for gastric and pancreatic cancers, and it is particularly prevalent in advanced stages of cancer.^{7,8}

Because of the pathophysiological complexity and multifactorial characteristics of this clinical syndrome, there is currently no effective treatment for cancer cachexia. Current research have focused on a multimodal approach,⁹ which includes adapted anticancer treatment^{10–12}; pharmacological treatment that aims in particular at reducing systemic inflammation, counteracting the hypercatabolic state of patients, and/or stimulating their appetite^{13,14}; nutrition care^{15–21}; adapted physical activity^{22–24}; and

psychosocial care.^{25,26} It is therefore essential to further improve our understanding regarding the interplay of the molecular mechanisms involved in the onset and progression of cancer cachexia. In particular, it is of crucial importance to better understand the pathophysiological basis of skeletal muscle atrophy, which represents a major clinical feature of cachexia.

To improve our knowledge of the factors regulating skeletal muscle mass loss, clinical studies are essential. The critical point for clinical studies investigating cancer cachexia is to identify cachectic vs. non-cachectic cancer patients groups. The clinical definition established by Fearon *et al.* distinguishes between cachectic patients and non-cachectic patients based on weight loss and body mass index.² This definition has subsequently been validated in an international multicentre study with 861 patients.²⁷ However, recent studies have demonstrated the importance of continually developing and updating these clinical criteria, which take into account the evolution of the overweight and obesity prevalence²⁸ or the advanced age of most cachectic patients.²⁹

The aim of this review was to offer an up-to-date synthesis of the data, which suggest the presence of alterations in skeletal muscle from cachectic cancer patients. In addition, we discuss the importance of a standardization for the diagnostic criteria of cancer cachexia, as well as the need for additional clinical studies to improve the robustness of the conclusions.

Methodology

Articles indexed in PubMed were queried to identify clinical studies, which have analysed skeletal muscle from cachectic cancer patients. Search terms included ‘[(cancer) OR (carcinoma) OR (tumor) OR (malignant) OR (metastasis)] AND [(cachexia) OR (sarcopenia) OR (weight loss) OR (malnutrition)] AND [(skeletal muscle) OR (muscle mass) OR (lean body mass) OR (rectus abdominis) OR (quadriceps)] ± [(biopsy) OR (biopsies)]’ ± filters: humans; adult: 19 + years; and publication dates from 01/01/1900 to 18/02/2020 were included. Among 749 publications identified through the database search, we excluded duplicates, review articles, preclinical studies, non-relevant or non-full-text clinical studies, as well as clinical studies where cachectic cancer patients were compared with healthy control patients.^{30–43} Importantly, in that case, it is not possible to distinguish between the specific effects of cachexia and cancer on the various parameters examined. We also excluded a case study, which was carried out on a cachectic cancer patient without comparison with a population of non-cachectic patients.⁴⁴ The identified articles were manually searched to identify additional relevant publications.

Thirty-one clinical studies were identified by this review of the literature (*Table 1*). The vast majority of these studies discuss patients with gastrointestinal cancer, including cancer of the oesophagus, stomach, liver, pancreas, colon, and anus. The main mechanisms studied cover the structure and typing of muscle fibres, pathways involved in proteolysis and protein synthesis, as well as lipid and mitochondrial metabolisms.

Skeletal muscle alterations in cancer cachexia

Structure and typing of muscle fibres

Up until now, cancer cachexia has mainly been studied in pre-clinical models generally characterized by transplantation of cancer cells or injection of carcinogens. The most studied and best described models are colon-26 adenocarcinoma⁷⁷ and Lewis lung adenocarcinoma.⁷⁸ In these models, the cross-sectional area of muscle fibres decreases,⁷⁹ and this atrophy is more likely to affect type II fibres.⁸⁰

In clinical studies, little is known about the possible alterations in the structure and typing of muscle fibres in patients with cancer cachexia (*Table 1*). Judge *et al.* have reported increased fibrosis and collagen content in skeletal muscle from cachectic pancreatic cancer patients.⁴⁵ Skeletal muscle ultrastructure also appears to be impaired, with an apparent disorganization and autophagosome formation in gastric cancer patients with cachexia.⁴⁶ The protein expression of myosin heavy chains, a major component of the muscular contractile system, was increased (for isoforms 1, 4, and 8),⁴⁷ decreased,⁴⁸ or unchanged⁴⁹ in cachectic patients with gastrointestinal cancer. Other muscular structural components have also been studied. The protein expression of actin and tropomyosin 1 and 2 was shown to be reduced^{47,48} while that of β -dystroglycan was increased, and those of β -sarcoglycan and dystrophin remained unchanged⁴⁹ in cachectic patients with gastrointestinal cancer. Skorokhod *et al.* also identified genes associated (positively for most of them) with cancer cachexia.⁵⁰ These genes are involved in muscle contraction and development (e.g. actin, titin, tropomyosin, and troponin) and actin cytoskeleton rearrangement (e.g. cofilin, dystonin, and vinculin) in pancreatic cancer patients.⁵⁰ While a significant reduction in the cross-sectional area of muscle fibres was observed in gastrointestinal cancer patients with cachexia and muscle loss,^{46,51} Op den Kamp *et al.* found no such change in cachectic patients with advanced non-small-cell lung cancer compared with pre-cachectic patients.⁵² Finally, no significant alteration in fibre typing associated with cancer cachexia has been reported in clinical studies, either of gastrointestinal^{51,53} or lung⁵⁴ cancer.

Table 1 Clinical studies on skeletal muscle alterations associated with cancer cachexia

Clinical study	Cancer	Population	Diagnostic criteria for CC	Muscle biopsy	Observations upon comparing CC vs. CNC patients
Judge <i>et al.</i> ⁴⁵	Pancreas Stages I–III	Healthy N = 16 (31% ♂) Cancer N = 20 (50% ♂) CC: 75% (NI% ♂)	WL > 5% in 6 months	RA	Increased fibrotic tissue and collagen content, which positively correlated with WL percentage ($P = 0.0016$, $r = 0.672$). No difference in fat deposition and no significant correlation with WL percentage. Significant decrease in myofibers cross-sectional area in patients with muscle loss \pm cachexia ($P < 0.05$). No difference for patients without muscle loss. Ultrastructure disorganization and autophagosome formation in CC patients. Increased protein and mRNA expression of autophagic-lysosomal (Beclin-1, LC3B, and p62) and ubiquitin-proteasome (MuRF1 and polyubiquitinated proteins) systems markers in CC patients (all $P < 0.05$).
Zhang <i>et al.</i> ⁴⁶	Stomach Stages I–III	Cancer N = 39 (72% ♂) CC: 56% (68% ♂)	WL > 5% in 6 months \pm muscle loss	RA	Comparison of proteomic signatures. In CC patients, reduced expression of TPM1, 2 and greater expression of MyHC1, 4, 8 (muscle contraction) compared with CNC. Deregulation of proteins in the mitochondrial electron transport chain and focal adhesion.
Ebhardt <i>et al.</i> ⁴⁷	Oesophagus, stomach, pancreas Stages NI	Healthy N = 18 (56% ♂) Cancer N = 19 (79% ♂) CC: 26% (60% ♂)	WL > 5%	Q	Significant decrease in protein expression of MyHC ($P = 0.036$), actin, Akt ($P = 0.001$), FOXO1 ($P = 0.011$), phosphorylated forms of FOXO3a ($P = 0.011$), mTOR ($P = 0.007$), and S6K ($P = 0.033$) in CC vs. CNC patients. Regulators of muscle contraction, protein synthesis, and protein degradation inhibitors.
Schmitt <i>et al.</i> ⁴⁸	Pancreas Stages II and IV	Healthy N = 3 Cancer N = 13 CC: 62% (38% ♂)	WL > 10% in 6 months	RA	Increased protein expression of β -dystroglycan (muscle structure) in CC vs. CNC patients. No modification of protein expression levels of MyHC, β -sarcoglycan, dystrophin (muscle structure), Akt, FOXO, MuRF1, MAFBx (muscle proteolysis), BNIP3, and GABARAPL1 (autophagy).
Stephens <i>et al.</i> ⁴⁹	Upper gastrointestinal Stages I–IV	Healthy N = 15 (53% ♂) Cancer N = 92 (72% ♂) CC: 55% (63% ♂)	WL \geq 5%	RA	Identification of 183 genes associated (positively for most of them) with CC. Some are involved in muscle contraction, rearrangement of the actin cytoskeleton, proteolysis, tissue hypoxia, and inflammatory response systems (e.g. over-regulated Egr-1).
Skorokhod <i>et al.</i> ⁵⁰	Pancreas Stages II–IV	Cancer N = 23 (61% ♂) CC: 43% (50% ♂)	WL > 10%	RA	Significant decrease in mean muscle fibre diameter in patients with muscle loss \pm WL (-25% , $P = 0.001$ and $P = 0.02$, respectively) compared with CNC patients. No difference for patients without muscle loss. No difference in fibre number or proportion of fibre type across all MyHC isoforms. Decrease in mean protein content and RNA/DNA ratio in patients with >5% WL or >2% WL + muscle loss compared with CNC patients. Increase in SMAD3 ($P = 0.022$ –atrophy), beclin, and ATG5 (autophagy— $P = 0.05$ and 0.01 , respectively) protein levels in patients with WL compared with CNC patients. No difference in ATG7 (autophagy), phospho-NF- κ B, or phospho-STAT3 (inflammatory cytokine signalling) protein levels.
Johns <i>et al.</i> ⁵¹	Upper gastrointestinal, Pancreas Stages NI	Cancer N = 41 (73% ♂) CC: 44% (61% ♂) ① or 27% (64% ♂) ② or 41% (65% ♂) ③	WL > 5% ① or 10% ② in 6 months or >2% + muscle loss ③	RA	No difference observed in the cross-sectional area of muscle fibres, protein concentration per unit of DNA, and muscle strength. No difference observed in the proteins of the Akt/FOXO pathway and of the UPS (including MuRF1 and MAFBx). Regarding the autophagic-lysosomal system, increased protein expression of BNIP3 in CC vs. CNC patients, no difference observed for LC3B. No difference observed for luciferase activity of NF- κ B, and for mRNA expression of I κ B α (NF- κ B inhibitor).
Op den Kamp <i>et al.</i> ⁵²	NSCLC Stages IIIb/IV	Healthy N = 22 (59% ♂) Cancer N = 26 (65% ♂) CC: 62% (56% ♂)	International consensus from 2011 ²	Q	

(Continues)

Table 1 (continued)

Clinical study	Cancer	Population	Diagnostic criteria for CC	Muscle biopsy	Observations upon comparing CC vs. CNC patients
Taskin et al. ⁵³	Gastrointestinal Stages NI	Healthy N = 5 (40% ♂) Cancer N = 14 (50% ♂) CC: 43% (33% ♂)	WL > 10% in 6 months	RA	Calcium sensitivity of the contractile apparatus is significantly increased in CC vs. CNC patients. No difference in absolute strength or ubiquitin protein polymers. Insignificant trend in a decrease in the ratio of MyHC I:IIa isoforms, indicating a higher number of fast muscle fibres in CC vs. CNC patients.
Op den Kamp et al. ⁵⁴	NSCLC Stages IIIb/IV	Healthy N = 22 (59% ♂) Cancer N = 26 (65% ♂) CC: 62% (56% ♂)	International consensus from 2011 ²	Q	No difference observed in fibre typing, oxidative, and glycolytic enzymatic activities, protein expression of mitochondrial respiratory chain complexes, and markers of mitochondrial biogenesis (PGC1 α and TFAM).
de Castro et al. ⁵⁵	Stomach, colorectal Stages I–IV	Cancer N = 44 (55% ♂) CC: 55% (67% ♂)	WL > 5% in 12 months maximum ⁵⁶ + C-reactive protein + Glasgow score + Cachexia Symptoms Questionnaires	RA	Increased mRNA expression of Fis1 (mitochondrial fission) ($P = 0.03$). No modification of the transcripts of Mfn2 (mitochondrial fusion), TFAM, and PGC1 α (mitochondrial biogenesis). Increase in the intermyofibrillar mitochondrial area in TEM ($P = 0.01$). No change in the number of copies of mitochondrial DNA. Increased protein expression of LC3II ($P = 0.02$), ATG5 ($P = 0.042$), and ATG7 ($P = 0.03$) (autophagy). Increased protein expression of activated caspases 8 ($P = 0.037$) and 9 ($P = 0.046$) and phosphorylated p53 ($P = 0.041$) (apoptosis).
Aversa et al. ⁵⁷	Several cancers Stages I–IV	Healthy N = 11 (64% ♂) Cancer N = 29 (59% ♂) CC: 41%	WL > 5% in 6 months	RA	Increased mRNA expression of LC3B and protein expression of LC3BI and Parkin, decreased mRNA expression of Parkin and PINK1 in CC vs. CNC patients ($P < 0.05$). No change regarding Beclin-1, p62, BNIP3, and Nix (autophagy/mitophagy markers).
Bossola et al. ⁵⁸	Stomach Stages I–IV	Healthy N = 14 (64% ♂) Cancer N = 23 (61% ♂)	None	RA	The specific chymotrypsin activity of the proteasome is increased when WL is $\geq 10\%$ ($P = 0.003$). No change in trypsin and peptidyl-glutamyl-peptidase activities.
Khal et al. ⁵⁹	Colorectum, pancreas Stages NI	Healthy N = 10 (80% ♂) Cancer N = 18 (67% ♂) CC: 72% (69% ♂)	WL moderate > 1%, severe > 11%	RA	Increase in mRNA and protein expression of proteasome 20S subunits and protein expression of E214k (ubiquitination), depending on WL (especially when it is between 10% and 20%).
Narasimhan et al. ⁶⁰	Pancreas, colorectum Stages I–IV	Cancer N = 40 (43% ♂) CC: 53% (38% ♂)	International consensus from 2011 ²	RA	Differential expression of 922 genes subjected to alternative splicing (772 up-regulated and 150 down-regulated) in CC vs. CNC patients. Genes involved in myogenesis, lipid biosynthesis, protein ubiquitination (and proteolysis) and inflammation associated positively, for the vast majority of them, with CC.
MacDonald et al. ⁶¹	Upper gastrointestinal Stages I–IV	Healthy N = 7 (42% ♂) Cancer N = 14 (57% ♂) CC: 57% (50% ♂)	WL $\geq 5\%$	RA + Q	Increased protein synthesis in CC vs. CNC patients (0.073% vs. 0.061% per hour, $P = 0.022$). Higher in Q vs. RA in CC ($P = 0.021$). No difference in proteolysis.
D'Orlando et al. ⁶²	Stomach Stages I–IV	Healthy N = 12 (58% ♂) Cancer N = 38 (66% ♂) CC: 18%	WL > 5% in 6 months	RA	No difference in mRNA expression of muscle atrophy genes (Atrogin-1, MuRF1, myostatin, and follistatin).
Rhoads et al. ⁶³	Stomach Stages Ib–IV	Healthy N = 10 (60% ♂) Cancer N = 14 (57% ♂)	None	RA	A more or less significant WL does not modify protein expression of I κ B α (NF- κ B inhibitor).
Stephens et al. ⁶⁴	Upper gastrointestinal Stages NI	Healthy N = 7 (71% ♂) Cancer N = 65 (71% ♂) CC: NI	WL $\geq 5\%$	RA + Q + D	Significant association between the mRNA expression of two genes activated by exercise and WL: CaMKII β in the RA ($r = 0.82$, $P = 0.01$), Q ($r = 0.45$, $P = 0.06$), and the D ($r = 0.50$, $P = 0.03$) and TIE1 in the RA ($r = 0.67$, $P = 0.01$) and Q ($r = 0.70$, $P = 0.003$). No correlation observed for E3 ubiquitin ligases and proteins of the Akt/FOXO pathway.

(Continues)

Table 1 (continued)

Clinical study	Cancer	Population	Diagnostic criteria for CC	Muscle biopsy	Observations upon comparing CC vs. CNC patients
Eley <i>et al.</i> ⁶⁵	Stomach, oesophagus Stages I–IV	Healthy <i>N</i> = 9 (10% ♂) Cancer <i>N</i> = 15 (87% ♂)	None	RA	No correlation between WL and the protein expression of the phosphorylated forms of PKR and eIF2 α (factors of inhibition of protein synthesis). The higher the WL, the lower the protein expression of myosin. WL severity does not influence the mRNA expression of ubiquitin.
Bossola <i>et al.</i> ⁶⁶	Stomach Stages I–IV	Healthy <i>N</i> = 10 (60% ♂) Cancer <i>N</i> = 20 (55% ♂)	None	RA	No difference in the percentage of apoptotic nuclei between patients with mild or moderate–severe weight loss.
Bossola <i>et al.</i> ⁶⁷	Stomach Stages I–IV	Healthy <i>N</i> = 5 (60% ♂) Cancer <i>N</i> = 16 (50% ♂) WL > 5%: 69% (45% ♂)	WL moderate > 5%, severe > 10%	RA	In cancer patients, the greater the WL, the more the number of intramyocellular lipid droplets increases ($r = 0.51$, $P = 0.025$). No correlation with the diameter of the lipid droplets.
Stephens <i>et al.</i> ⁶⁸	Oesophagus, stomach, pancreas + others Stages II–IV	Healthy <i>N</i> = 6 (33% ♂)	None	RA	Depending on the diagnostic criteria for CC, the SNPs associated with CC as well as their degree of association (P value) differ. When WL > 10%, the highlighted SNPs participate in the regulation of appetite ($P = 0.004$), adhesion ($P = 0.005$), structure and function of the cell membrane ($P = 0.037$), and signal transduction ($P = 0.038$). When WL > 15%, they only participate in cell adhesion ($P = 0.019$). When WL > 2% and the SMI is low, they participate in the regulation of appetite ($P = 0.014$), signal transduction ($P = 0.023$), glucocorticoid-regulated pathway ($P = 0.034$), and in lipid metabolism ($P = 0.039$).
Johns <i>et al.</i> ⁶⁹	Several cancers Stages I–IV	Cancer <i>N</i> = 19 (58% ♂) Total <i>N</i> = 1276 (61% ♂) CC: NI	WL > 5% or 10% or 15% or low SMI + WL > 2%	RA	Identification of eight new miRNAs associated with CC and participating in particular in pathways regulating lipid biosynthesis, myogenesis, inflammation, and the innate immune response. No difference in protein expression of Mfn2, OPA1 (mitochondrial fusion), PINK1, and Parkin (mitophagy) or in mRNA expression of Fis1 PGC1 α and TFAM (mitochondrial biogenesis). mRNA expression of Fis1 (mitochondrial fission) and protein expression of LC3BI (autophagy) increased in CC vs. CNC patients ($P < 0.05$). Increased mRNA expression of UCP-3 in weight-losing cancer patients compared with weight-stable cancer patients ($P < 0.02$). No difference in mRNA expression of UCP-2.
Narasimhan <i>et al.</i> ⁷⁰	Pancreas, colorectum Stages I–IV	Cancer <i>N</i> = 42 (43% ♂) CC: 52% (41% ♂)	International consensus from 2011 ²	RA	No difference in mRNA expression of satellite cell markers (Pax3 and Pax7), early (MyoD and Myf5) and late myogenesis (MyoG), autophagic factor (p62), and antioxidant defence genes (SOD2, GCLM, NSF2, and HSP1a).
Marzetti <i>et al.</i> ⁷¹	Stomach Stages I–IV	Healthy <i>N</i> = 9 (89% ♂) Cancer <i>N</i> = 18 (94% ♂) CC: 50% (89% ♂)	WL > 5% in 6 months	RA	No difference in mRNA expression of IL-4, IL-4R, and IL-13R (inflammatory markers).
Collins <i>et al.</i> ⁷²	Gastrointestinal Stages NI	Healthy <i>N</i> = 6 (33% ♂) Cancer <i>N</i> = 12 (92% ♂) CC: 50% (100% ♂)	WL	RA	Positive correlation between protein content and skeletal muscle radiodensity on CT scan ($r = 0.406$, $P = 0.021$), as well as WL ($r = 0.416$, $P = 0.018$).
Brzeszczyńska <i>et al.</i> ⁷³	Oesophagus, stomach, pancreas Stages II–III	Healthy <i>N</i> = 41 (80% ♂) Cancer <i>N</i> = 28 (75% ♂) CC: 36% (80% ♂)	WL > 5%	Q	
Prokopchuk <i>et al.</i> ⁷⁴	Pancreas Stages I–IV	Healthy <i>N</i> = 19 (37% ♂) Cancer <i>N</i> = 25 (32% ♂) CC: 48% (25% ♂)	WL > 10% in 6 months	RA	
Ramage <i>et al.</i> ⁷⁵	Upper gastrointestinal Stages I–IV	Cancer <i>N</i> = 32 (81% ♂) CC: 47%	WL > 5%	RA	

(Continues)

Table 1 (continued)

Clinical study	Cancer	Population	Diagnostic criteria for CC	Muscle biopsy	Observations upon comparing CC vs. CNC patients
Sun <i>et al.</i> ⁷⁶	Stomach Stages I–IV	Healthy N = 29 (72% ♂) Cancer N = 102 (71% ♂)	None	RA	Significant association between mRNA expression of ubiquitin and TRAF6 with WL ($P = 0.001$ for both).

Akt or PKB, protein kinase B; ATG5/7, autophagy-related 5/7; BNIP3, BCL2 interacting protein-3; CaMKII β , calcium/calmodulin-dependent protein kinase-II β ; CC, cancer cachectic; CNC, cancer non-cachectic; CT, computed tomography; D, diaphragm muscle; E214k, 14 kDa ubiquitin-conjugating enzyme; eIF2 α , eukaryotic initiation factor-2 α ; Egr-1, early growth response protein-1; Fis1, mitochondrial fission protein-1; FOXO, forkhead box O protein; GABARAPL1, GABA type A receptor associated protein like-1; GCLM, glutamate-cysteine ligase modifier subunit; HSP1, heat shock 70 kDa protein-1; Ikb α , nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor- α ; IL, interleukin; LC3B or MAP 1-LC3B, microtubule-associated protein 1-light chain 3 beta; MAFBx or atrogin-1, muscle atrophy F-box; Mfn, mitofusin; mTOR, mechanistic target of rapamycin; MuRF1, muscle RING finger-1; MyHC, myosin heavy chains; MyoD, myoblast determination protein-1; Myf5, myogenic factor-5; MyoG, myogenin; NF- κ B, nuclear factor of kappa light polypeptide gene enhancer in B-cells; NI, not indicated; Nix or BNIP3-like, NRF2, or NFE2L2, nuclear factor gamma coactivator 1- α ; PINK1, PTEN-induced kinase-1; PKR, protein kinase R; Q, quadriceps; RA, rectus abdominis; S6K1, protein S6 kinase 1; SMAD3, mothers against decapentaplegic homologue 3; SMI, skeletal muscle index; SNP, single nucleotide polymorphism; SOD2, superoxide dismutase-2; STAT3, signal transducer and activator of transcription 3; TEM, transmission electron microscopy; TFAM, mitochondrial transcription factor A; TIE1, tyrosine kinase with immunoglobulin-like and EGF-like domains-1; TPM, tropomyosin; TRAF6, tumour necrosis factor receptor (TNFR)-associated factor-6; UCP, uncoupling protein; UPS, ubiquitin-proteasome system; WL, weight loss.

Muscle proteolysis and protein synthesis

In preclinical studies of cancer cachexia, there is abundant evidence for increased proteolysis, particularly through autophagy and the ubiquitin–proteasome system (UPS), and decreased protein synthesis in skeletal muscle (see review^{81–83}). Activation of NF- κ B by inflammatory cytokines may result in muscle wasting in mouse models.⁸⁴ NF- κ B induces the transcription of UPS genes, which activation has also been observed in preclinical models.^{82,83} Apoptotic processes may also, at least in part, be responsible for muscle atrophy, as suggested by the data from different preclinical studies.^{85–88}

However, results from clinical studies are much more controversial (Table 1). Some studies have reported an increased expression of autophagy markers (Beclin-1, LC3B, ATG5, ATG7, and p62)^{46,51,55,57} and of UPS proteins (MuRF1 and polyubiquitinated proteins),⁴⁶ as well as muscle atrophy-inducing pathway regulators (SMAD3)⁵¹ in cachectic patients with mainly gastrointestinal cancer. Increased proteasome activity in gastric cancer⁵⁸ and increased protein expression of proteasome 20S subunits in colorectal and pancreatic cancers⁵⁹ were also reported. Narasimhan *et al.* and Skorokhod *et al.* have identified many genes positively (e.g. protein degradation and ubiquitination genes) associated with cancer cachexia in pancreatic and/or colorectal cancer patients.^{50,60} Schmitt *et al.* have observed a decrease in the expression of actors involved in protein synthesis and inhibition of protein degradation pathways (Akt, FOXO, mTOR, and S6K) in pancreatic cancer.⁴⁸ However, numerous clinical studies have found no impairment in the signalling pathways involved in the regulation of proteolysis and protein synthesis in skeletal muscle from cachectic patients.^{49,52,53,61,62} In many cases, no association with weight loss was observed^{63–66} in gastrointestinal and pulmonary cancers. Johns *et al.* reported no difference in the levels of muscle atrophy inflammatory mediators phospho-NF- κ B and phospho-STAT3 protein levels in gastrointestinal cancer patients with cachexia.⁵¹ Regarding apoptotic pathways, de Castro *et al.* have observed an increased expression of several well-known markers (activated caspases 8 and 9 and phosphorylated p53) in gastrointestinal cancer patients with cachexia.⁵⁵ However, Bossola *et al.* have reported unchanged number of apoptotic myonuclei when comparing gastric cancer patients with mild or moderate–severe weight loss.⁶⁷

Myosteatorsis

Myosteatorsis, which is defined as a pathological fat accumulation in skeletal muscle, has been studied in a preclinical tumour-bearing model (Ward colon tumour model).⁸⁹ In that case, the authors observed increased neutral lipids and total triglyceride content within the rat *gastrocnemius* muscle fibres. This observation is indicative of the presence of lipid

droplets, as well as increased mRNA levels of key transcription factors involved in adipocyte gene expression (i.e. C/EBP δ , C/EBP α , and PPAR γ).

In cachectic cancer patients, weight loss has been associated with a greater number of intramyocellular lipid droplets, as observed by electron microscopy of abdominal muscle biopsies.⁶⁸ In the clinical practice, studies of skeletal muscle radiological attenuation by computed tomography scan have shown that it is very variable in cancer patients. Its decrease may, at least in part, reflect an accumulation of intramuscular lipids^{90,91} and is associated with shorter survival.⁹² The specific pathophysiological mechanisms that lead to myosteatosis have not yet been well-characterized. Transcriptomic analyses have suggested that disruption in oxidative phosphorylation and lipid accumulation may contribute to myosteatosis, as observed in abdominal skeletal muscle biopsies of patients with pancreatic or periampullary cancer and with significantly low radiological attenuation of skeletal muscle on computed tomography scan.⁹³ Genetic and transcriptomic studies of skeletal muscle biopsies obtained from cachectic patients (mainly gastrointestinal cancers) have identified single nucleotide polymorphism⁶⁹ and miRNA⁷⁰ involved in lipid biosynthesis (Table 1). Narasimhan *et al.* also found alternatively spliced genes, which are mostly up-regulated, and encode enzymes and binding proteins from the lipid biosynthesis pathways.⁶⁰

Mitochondrial metabolism

Previous studies have suggested an association between mitochondria dysfunctions and skeletal muscle atrophy.^{94,95} Several preclinical and clinical studies have therefore investigated mitochondrial metabolism dysregulation in skeletal muscle in the context of cancer cachexia. Muscle atrophy associated with mitochondrial dysfunctions has been observed in cachectic rodents. Among these dysfunctions, several parameters have been described, and they include increased mitochondrial surface^{96,97}; impairment of mitochondrial dynamics such as increased fission (Fis1), decreased fusion (Mfn1 and Mfn2), or biogenesis (PGC1 α)⁹⁸; a decrease in the activity of the respiratory chain complexes^{99–101}; and an increase in UCP-2 and UCP-3 gene expression,^{102,103} a questionable indicator of mitochondrial energy coupling. The study by Brown *et al.* on preclinical models of cancer cachexia suggested that alterations in dynamics (biogenesis and fusion), mitochondrial quality, and function precede muscle atrophy and that a decrease in mitochondrial protein content as well as an increase in mitophagy appears at a later stage of cachexia.¹⁰⁴

Regarding clinical studies, mitochondrial metabolism has rarely been studied in the context of cancer cachexia (Table 1). A recent clinical study by de Castro *et al.*, including patients with gastric or colorectal cancer, revealed an increase

in Fis1 mRNA expression in skeletal muscle from cachectic patients compared with non-cachectic, but there was no modification in the levels of the fusion marker (Mfn2) and mitochondrial biogenesis transcripts (TFAM and PGC1 α).⁵⁵ On the other hand, they showed by electron microscopy that there was an increase in the intermyofibrillary mitochondrial area, without modification in the number of mitochondrial DNA copies. This finding could illustrate the absence of modification in mitophagy activity. The authors suggested that these last observations supported the results from the preclinical study by Brown *et al.* who showed that impaired mitochondrial protein content and increased mitophagy only appear at a much later stage in cancer cachexia.¹⁰⁴ Similarly, Marzetti *et al.* have observed an increase in Fis1 transcript levels and no change in mRNA or protein expression levels of markers of mitochondrial fusion (Mfn2 and OPA1) and mitochondrial biogenesis (PGC1 α and TFAM) in cachectic patients with gastric cancer.⁷¹ Op den Kamp *et al.* have also reported an absence of modification of the protein expression of the same markers of mitochondrial biogenesis (PGC1 α and TFAM), as well as complexes of the respiratory chain in cachectic patients suffering from pulmonary cancer.⁵⁴ On the other hand, Collins *et al.* have observed increased UCP-3 (but not UCP-2) mRNA expression levels in patients with gastrointestinal adenocarcinoma experiencing weight loss.⁷² This finding suggests that increased proton leak may contribute to skeletal muscle catabolism through enhancement of energy expenditure. However, increase in skeletal muscle UCP-3 mRNA is a poor index of mitochondrial energy coupling. Finally, to our knowledge, it is important to note that no clinical study has explored the mitochondrial functionality in skeletal muscle from cachectic cancer patients.

Discussion and other perspectives

The overall result of clinical studies suggests the presence of alterations in skeletal muscle from cachectic cancer patients (Table 1). These alterations may affect the structure of muscle fibres, the different pathways involved in proteolysis and protein synthesis, lipid metabolism (myosteatosis), and mitochondrial metabolism (i.e. mitochondrial surface and dynamics and mitochondrial DNA).

It is important to note that for most of the parameters studied, which could play a role in muscle wasting, the results of clinical studies diverge (Table 1). A possible explanation for these differences may be the lack of well-established diagnostic criteria. An improvement and better standardization of the diagnostic criteria used for cancer cachexia identification is utterly necessary. These criteria should include key cachexia symptoms such as weight loss, taking body mass index into account,²⁸ muscle wasting,^{105,106} appetite loss, performance status, and blood chemistry. On the basis of these

key components, Zhou *et al.* have proposed a clinically applicable score for the classification of the various cachexia stages observed in cancer patients.¹⁰⁷ De Castro *et al.* have also used combined diagnostic criteria to discriminate cachectic and non-cachectic cancer patients.⁵⁵ To better improve patient care, it would be preferable to diagnose patients as soon as possible, possibly at a pre-cachectic state. Early diagnosis can reduce the risk of transition to a cachectic state with an appropriate choice of therapeutic and supportive regimens. But current diagnostic criteria are insufficient and inadequate to allow a good distinction between pre-cachectic and non-cachectic patients.²⁷ New clinical trials testing muscle bioptic and biochemical/metabolic parameters are necessary to develop validated criteria.

Besides diagnostic criteria, more obvious factors may explain why the results of clinical studies on skeletal muscle alterations in cancer cachexia diverge (*Table 1*): (i) The heterogeneity of the cohorts, sometimes with several types of cancer and a disproportionate distribution of these types between the cachectic and non-cachectic groups. At this time, we cannot exclude that each cancer can differently regulate cancer cachexia. Additionally, there is a disproportionate distribution of men and women between groups. Sexual dimorphism exists for several skeletal muscle parameters, and hormonal differences may also have a significant impact on cancer cachexia pathophysiology.^{108–110} (ii) Muscular localization of biopsies. Most samples were collected from the *rectus abdominis*, but some clinical studies have used biopsies from the *quadriceps*^{47,52,54,61,64,73} or diaphragm muscle.⁶⁴ (iii) The number of patients included is often very small and cannot provide sufficient statistical power. Thirteen of 31 clinical studies had a total number of cancer patients ≤ 20 , and there were < 30 patients in 20 studies, with a prevalence of cachexia of around 50% most of the time. (iv) Methods of analysis. Some studies have relied on mRNA expression, while others have compared protein expression or enzyme activity. These differences may explain the varying results in clinical studies on muscle proteolysis.

Several blood components have been proposed to aid in the diagnosis of malnutrition/cancer cachexia in patients. Numerous recent clinical studies have observed an association between the components listed hereafter and the cachectic state of patients (*Table 2*): (i) markers of inflammation: C-reactive protein; interleukins IL-1, IL-6, IL-8, IL-10; IFN- γ ; and TNF- α ; (ii) members of the TGF- β family: myostatin, activin A, and GDF-15; (iii) factors derived from the tumour: ZAG (or LMF), VEGF, and Midkine; (iv) lipolysis markers of the adipose tissue: leptin, adiponectin, resistin, free fatty acids, and glycerol; and (v) others: ghrelin, IGF-1, albumin, and angiotensin II. Other factors have also been studied, and they include the proteolysis-inducing factor¹²¹ and markers of muscle degradation: 3-methylhistidine, titin fragments, collagen fragments,¹²² testosterone,¹²³ and the parathyroid hormone-related protein.¹²⁴ Nevertheless, there is

currently not enough clinical evidence to conclude on their validity. To date, there is no validated biomarker for cancer cachexia.

In addition to variation in the levels of factors discussed before, heterogeneity in blood analysis data may also be due to the fact that concentrations of markers, such as IL6, TNF α , and leptin, may vary between day and intraday.¹²⁵ These values may be partly associated to the patient's circadian rhythm and/or metabolic status.

It is interesting to note that C-reactive protein does not appear to be modulated by circadian rhythm or metabolic status.^{126,127} Despite this observation, levels of C-reactive protein, which is a well-accepted marker of systemic inflammation, are not consistently increased in populations of patients with cancer cachexia^{49,50,57,74,111,112} (*Table 2*). This observation challenges the use of C-reactive protein in the clinic as a complementary biomarker for cancer cachexia diagnosis.

Considering the conflicting results obtained using muscle biopsies from cachectic patients, no specific biomarker of cancer cachexia has been identified at muscle levels. Myokines, such as myostatin, irisin, activin A, IL-15, FGF21, and GDF-15, were also considered as possible biomarkers and therapeutic targets in cancer cachexia (see review¹²⁸) (*Table 2*). The advantage of dosing muscle cytokines is that it is less invasive than collecting biopsy to evaluate muscle wasting. But more clinical data are needed to confirm this suggestion.

Data extracted from preclinical and clinical studies are also ambivalent. While most preclinical studies observed increased proteolysis and mitochondrial metabolism dysregulations in cachectic rodents, such alterations were not reported in numerous clinical studies on cancer cachexia. Petruzzelli and Wagner hypothesized that these differences were due to the severity of cachexia.¹²⁹ Rodent studies are generally carried out during or after rapid and drastic weight loss, while muscle wasting is much more progressive in cachectic patients. The mismatch between the clinical reality and animal models could at least partly contribute to the poor translation observed in the field (see review¹³⁰).

Even if there are discrepancies in the results of clinical studies, this review suggests the presence of defects in the structure of muscle fibres, increase in proteolysis, decrease in protein synthesis, alterations in lipid metabolism (myosteatosis), and dysfunctions in mitochondrial structure and metabolism (mitochondrial surface and dynamics and mitochondrial DNA) (*Table 1*). Taken together, these observations suggest associations between structural and metabolic alterations that may, at least in part, be responsible for the skeletal muscle atrophy characteristics observed in cancer cachexia.

In addition to these parameters, it is interesting to note that endoplasmic reticulum (ER) stress has recently been studied in the context of cancer cachexia (see review¹³¹).

Table 2 Recent clinical studies looking for potential biomarkers of cancer cachexia

Clinical study	Cancer, population	Diagnostic criteria for CC	Observations upon comparing CC vs. cancer non-cachectic patients
Stephens et al. ⁴⁹	Gastrointestinal Stages I-IV N = 92, CC: 55%	Weight loss \geq 5%	C-reactive protein, mg/L 18.3 (\pm 32.6) vs. 12.0 (\pm 29.6), P = ns
Skorokhod et al. ⁵⁰	Pancreas Stages II-IV N = 23, CC: 43%	Weight loss > 10%	C-reactive protein, NI 11.6 (3.1-25.6) vs. 7.3 (5.7-11.8), P = ns
Aversa et al. ⁵⁷	Several cancers Stages I-IV N = 29, CC: 52%	Weight loss > 5% in 6 months	C-reactive protein, mg/dL 2.07 (\pm 0.98) vs. 1.92 (\pm 1.04), P = ns
Prokopchuk et al. ⁷⁴	Pancreas Stages I-IV N = 25, CC: 48%	Weight loss > 10% in 6 months	C-reactive protein, mg/dL 0.3 (0.1-4.7) vs. 1.0 (0.1-4.0), P = ns
Agustsson et al. ¹¹¹	Several cancers Stages I-IV N = 40, CC: 32.5%	Weight loss > 5% in 3 months or > 10% in 6 months	C-reactive protein, μ g/L 26.9 (\pm 11.6) vs. 4.9 (\pm 2.2), P = ns Leptin, ng/mL \downarrow 4.5 (\pm 0.6) vs. 9.0 (\pm 1.5), P < 0.05 Albumin, g/L 35.1 (\pm 1.3) vs. 37.2 (\pm 0.9), P = ns C-reactive protein, mg/dL 3.0 (\pm 4.0) vs. 1.6 (\pm 2.3), P = 0.22
Kim et al. ¹¹²	Colorectal, lung Stages I-IV N = 42, CC: 50%	Weight loss \geq 5% in 6 months	C-reactive protein, mg/dL 369.4 vs. 282.9, P = 0.809 IL-1 α , pg/mL 7.1 vs. 6.8, P = 0.913 IL-1 β , pg/mL 30.4 vs. 21.9, P = 0.117 IL-6, pg/mL 48.9 vs. 41.7, P = 0.764 IL-8, pg/mL 20.6 vs. 17.0, P = 0.374 IL-10, pg/mL \uparrow ~21 vs. ~3, P < 0.0001 C-reactive protein, mg/L \uparrow ~40 vs. ~15, P = 0.0054 IL-6, pg/mL \uparrow ~60 vs. ~20, P = 0.001 IL-8, pg/mL
Lerner et al. ¹¹³	Several cancers Stages NI N = 92, CC: 53%	Not clearly specified, Maybe Fearon et al. ²	IFN- γ , pg/mL 217.8 vs. 211.5, P = 0.779 TNF- α , pg/mL 126.0 vs. 105.8, P = 0.665 VEGF, pg/mL 49.4 vs. 36.4, P = 0.286 Activin A, ng/mL \uparrow 1.1 vs. 0.6, P = 0.028 GDF15, ng/mL \uparrow 5.0 vs. 2.7, P = 0.025 TGF- β 1, pg/mL \uparrow ~22 000 vs. ~10 000, P < 0.0001
Penafuerte et al. ¹¹⁴	Several cancers Stages III-IV N = 122, CC: 50.8%	International consensus from 2011 ²	Albumin, mg/L \downarrow ~35 vs. ~41, P = 0.0027 Angiotensin II, pg/mL \uparrow ~17 vs. ~8, P = 0.022 Active A, pg/mL \uparrow 558 (228-17 660) vs. 397 (165-2731), P < 0.001 Myostatin, pg/mL \downarrow 1371 (167-4989) vs. 2109 (715-4907), P < 0.001 TNF- α , pg/mL \uparrow 72.5 (\pm 29) vs. 13.8 (\pm 4.3), P = 0.046 Leptin, pM \downarrow 221 (\pm 191) vs. 309 (\pm 271), P = ? Adiponectine, μ g/mL \uparrow 19.1 (\pm 7.3) vs. 11.1 (\pm 8.5), P = 0.010 TNF- α , pg/mL 5.0 (3-7.8) vs. 4.0 (2.9-6.2), P = ns
Loumaye et al. ¹¹⁵	Colorectal, lung Stage I-IV N = 152, CC: 49%	International consensus from 2011 ²	Albumin, g/dL \uparrow 1.3 (0.1-25.7) vs. 0.3 (0.0-10.3), P < 0.001 Albumin, g/dL \downarrow 4.2 (2.8-5.0) vs. 4.5 (3.0-5.1), P < 0.001 C-reactive protein, μ g/mL \uparrow 24.9 (\pm 14) vs. 14.9 (\pm 13), P = 0.015 IL-6, pg/mL \uparrow 160 (\pm 58) vs. 30.3 (\pm 8.2), P = 0.011 IL-10, pg/mL 24.3 (\pm 19) vs. 4.9 (\pm 3.6), P = ns C-reactive protein, mg/dL \uparrow 3.5 (\pm 1.1) vs. 1.8 (\pm 0.8), P = 0.03 ZAG, μ g/mL \uparrow 40.3 (34.5-56.5) vs. 28.9 (23.8-30.3), P = 0.001
Batista et al. ¹¹⁶	Gastrointestinal Stages I-IV N = 43, CC: 72%	Weight loss > 5% in 3 months or > 10% in 6 months	
Burney et al. ¹¹⁷	Several cancers Stages I-IV N = 95, CC: 47%	IMC < 35 kg/m ² Weight loss > 5% in 6 months	
Felix et al. ¹¹⁸	Pancreas Stage II	Weight loss > 12% in 6 months	

(Continues)

Table 2 (continued)

Clinical study	Cancer, population	Diagnostic criteria for CC	Observations upon comparing CC vs. cancer non-cachectic patients	
Kerem et al. ¹¹⁹	N = 33, CC: 70% Stomach	Perte d'IMC > 10% in 6 months	IFN- γ , pg/mL	
			Albumin, g/dL	
	Stages I–IV	N = 30, CC: 50%	IL-1 β , pg/mL	
			IL-6, pg/mL	
Krzysztek-Korpacka et al. ¹²⁰	Stomach, oesophagus	Weight loss \geq 5% in 3 months	Resistin, ng/mL	
			Leptin, pg/mL	
			IL-1, pg/mL	
	Stages II–IV	N = 96, CC: 51%		VEGF-A, pg/mL
				VEGF-C, ng/mL
				Midkine, pg/mL

CC, cancer cachectic; NI, not indicated; ns, non-significant.

An increase in the transcript levels (IRE1 α , XPB-1, ATF6, and DR5) and in protein levels (CHOP and phospho-eIF2 α) of certain ER stress markers has been reported in Lewis lung adenocarcinoma mice. These observations demonstrate that ER stress-induced compensatory unfolding protein response (UPR) is increased in skeletal muscle from cachectic mice.¹³² Furthermore, this preclinical study suggests a close relationship between ER stress-induced UPR and muscle proteolysis¹³² (see reviews^{133,134}). Furthermore, an increase in gene expression of ER stress-induced UPR markers has recently been reported in the *vastus lateralis* muscle in cachectic patients with lung cancer.¹³⁵ However, cancer cachectic patients were compared with healthy controls in this study.

How can the parameters cited previously be associated with muscle wasting? (Figure 1) Myosteatosis is defined by lipid droplets accumulation in muscle. An accumulation of toxic lipid intermediates, such as ceramides and diacylglycerol, in lipid droplets may lead to increased proteolysis and decreased protein synthesis through inhibition of the Akt pathway¹³⁶ (Figure 1). These toxic lipid intermediates may also induce ER stress.¹³⁶ To restore ER homeostasis, several triggers of the UPR may be activated. They include PERK, which may induce a decrease in protein synthesis through the ATF4 pathway.¹³⁷ Intramuscular lipid accumulation may also cause dysfunctions in mitochondrial metabolism, through an inhibition of the electron transport chain and fatty acid β -oxidation.¹³⁶ Conversely, alterations in mitochondrial metabolism could limit fatty acid β -oxidation, accentuate the accumulation of lipid droplets, and thereby create a vicious circle. Deterioration of mitochondrial metabolism may also actively participate in muscle wasting via the production of reactive oxygen species. Mitochondria and ER can interact via specific contact sites termed mitochondria-associated ER membranes, which are necessary for several key processes, such as the formation of autophagosomes, the regulation of mitochondrial morphology, dynamics, quality control, calcium transport from the ER to the mitochondria, lipid synthesis and transport, proteolysis, as well as cell death.^{138,139} Impairment of mitochondria-associated membrane function could worsen dysfunctions in mitochondrial and lipid metabolisms and participate in the increase proteolysis, thereby inducing atrophy of skeletal muscle fibres and a decrease in skeletal muscle mass.

Skeletal muscle metabolism degradation during cancer cachexia has been poorly investigated in the context of obesity. Cancer-induced skeletal muscle wasting and obesity present common skeletal muscle pathological mechanisms, such as insulin resistance, inflammatory state, and oxidative stress. Indeed, obesity predisposes to a pro-inflammatory state via increased inflammatory mediators, such as TNF- α and IL-6, which stimulate the liver to synthesize and secrete C-reactive protein. It is also associated with reduced levels of adiponectin, which has anti-inflammatory function (see




Figure 1 Summary of the hypothetical associations between metabolic and structural dysfunctions that may, at least in part, be responsible for skeletal muscle atrophy in cachectic cancer patients and for the aggravating role of obesity. In red are represented our hypotheses on the effects of cancer cachexia and in green, our hypotheses on the effects of obesity. An accumulation of lipid droplets, mitochondrial dysfunctions, and endoplasmic reticulum (ER) stress could lead to increased proteolysis, via the ubiquitin–proteasome system (UPS) and autophagy, and decreased protein synthesis, both of which induce atrophy of skeletal muscle fibres and loss of muscle mass. The production of reactive oxygen species (ROS) following mitochondrial alterations may also participate in muscle wasting, by activating apoptotic pathways. In the adipose compartment, lipolysis, which is increased in obese patients, could lead to a greater accumulation of lipid droplets in muscle fibres, mitochondrial dysfunctions, and disturbances in the integrity of mitochondria-associated ER membranes (MAMs), which may worsen skeletal muscle atrophy.

review¹⁴⁰). This moderate inflammatory state might accelerate cancer-induced cachexia. Effects of obesity on cancer cachexia are currently debated in the scientific community. While some scientists discuss the paradoxically protective effect of obesity,¹⁴¹ due to higher fat reserves, which would preserve from a deleterious weight loss, others highlight the danger of unseen muscle wasting.¹⁴² It has been suggested that the alterations of adipose tissue (when it occurs) precede muscle wasting in the development of cancer cachexia.^{143,144} Adipose tissue secretes adipokines, especially in the context of obesity (see review¹⁴⁵), which may have a direct effect on skeletal muscle metabolism: leptin, adiponectin, resistin, and visfatin are known mediators of tissue inflammation and insulin sensitivity (see reviews^{146,147}). Skeletal muscle may also release myokines, such as IL-6 and IL-15, which may increase white adipose tissue lipolysis/lipogenesis ratio.^{128,148,149} A vicious circle may exist between the increased adiposity and skeletal muscle wasting, especially because of the reciprocal influence exerted by these two tissues (see review¹⁵⁰). For instance, adipose tissue lipolysis may induce myosteatosis. In obese patients, basal

lipolysis has been reported to be increased in subcutaneous fat cells, because of their larger surface area associated with the secretion of inflammatory cytokines, such as TNF- α .¹⁵¹ Excessive lipolysis leads to elevated fatty acid availability for skeletal muscle cells. Overloaded muscle fibres may present increased lipid droplet content (size and/or number), which leads to lipotoxic intermediate accumulation. In this context, muscle proteolysis, mitochondrial dysfunctions, and mitochondrial production of reactive oxygen species should be increased, which aggravates skeletal muscle wasting (Figure 1). Potes *et al.* demonstrated that excess weight is associated with increased ER stress marker levels in human *vastus lateralis*.¹⁵² But further studies need to be performed in patients suffering from cancer cachexia to verify the presence or absence of ER stress and its interplay with the other molecular mechanisms involved in the onset and progression of cancer cachexia.

Similarly to this adipose tissue–muscle crosstalk, other tissues might affect the skeletal muscle: (i) liver acute-phase proteins, such as serum amyloid A, could participate in activating muscle wasting by enhancing proteolysis (see

review¹⁵³); (ii) in the context of cancer with bone metastases, osteolysis induces the secretion of activin and TGF- β , which are mediators of muscle proteolysis¹⁵⁴; (iii) gut barrier dysfunction leads to increasing intestinal permeability of pathologic bacteria and endotoxemia and perpetuates systemic inflammation known to drive muscle wasting¹⁵⁵; and (iv) interactions between systemic and brain inflammation¹⁵⁶ alter the activity of the hypothalamus, responsible for the regulation of anorexia¹⁵⁷ and for the secretion of glucocorticoids, which stimulate proteolysis in skeletal muscle.¹⁵⁸

Conclusion

The overall result of clinical studies suggests the presence of alterations in skeletal muscle from cachectic cancer patients, and these alterations could affect myofibers structure, proteolysis, and protein synthesis pathways, as well as lipid and mitochondrial metabolisms. However, evidences are still weak because clinical studies have often obtained contradictory results. Additional clinical studies are essential to further the exploring and understanding of alterations underlying skeletal muscle wasting characteristic of cancer cachexia. Moreover, an improvement and better standardization of the diagnostic criteria for cancer cachexia is crucial to ameliorate the robustness of the conclusions.

References

- Warren S. The immediate causes of death in cancer. *Am J Med Sci* 1932;**184**:610–615.
- Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. *Lancet Oncol* 2011;**12**:489–495.
- Johns N, Stephens NA, Fearon KCH. Muscle wasting in cancer. *Int J Biochem Cell Biol* 2013;**45**:2215–2229.
- Fearon KCH, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signalling, and metabolic pathways. *Cell Metab* 2012;**16**:153–166.
- Fearon KCH, Moses AGW. Cancer cachexia. *Int J Cardiol* 2002;**85**:73–81.
- Sun L, Quan X-Q, Yu S. An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. *Nutr Cancer* 2015;**67**:1056–1062.
- Vagnildhaug OM, Balstad TR, Almberg SS, Brunelli C, Knudsen AK, Kaasa S, et al. A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. *Support Care Cancer* 2018;**26**:1871–1880.
- von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. *J Cachexia Sarcopenia Muscle* 2010;**1**:1–5.
- Madeddu C, Maccio A, Mantovani G. Multitargeted treatment of cancer cachexia. *Crit Rev Oncog* 2012;**17**:305–314.
- Coletti D. Chemotherapy-induced muscle wasting: an update. *Eur J Transl Myol* 2018;**28**:7587.
- Damrauer JS, Stadler ME, Acharyya S, Baldwin AS, Couch ME, Guttridge DC. Chemotherapy-induced muscle wasting: association with NF- κ B and cancer cachexia. *Eur J Transl Myol* 2018;**28**:7590.
- Hopkins JJ, Sawyer MB. Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments. *Cancer Chemother Pharmacol* 2018;**82**:1–29.
- Sadeghi M, Keshavarz-Fathi M, Baracos V, Arends J, Mahmoudi M, Rezaei N. Cancer cachexia: diagnosis, assessment, and treatment. *Crit Rev Oncol Hematol* 2018;**127**:91–104.
- Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. *Curr Oncol Rep* 2017;**19**:3.
- Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. *Clin Nutr* 2017;**36**:11–48.
- Fitschen PJ, Wilson GJ, Wilson JM, Wilund KR. Efficacy of β -hydroxy- β -methylbutyrate supplementation in elderly and clinical populations. *Nutr Burbank Los Angel Cty Calif* 2013;**29**:29–36.
- Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)—a randomized multicentre trial. *Nutr J* 2012;**11**:52.
- Ries A, Trottenberg P, Elsnér F, Stiel S, Haugen D, Kaasa S, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. *Palliat Med* 2012;**26**:294–304.
- Murphy RA, Mourtzakis M, Chu QSC, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. *Cancer* 2011;**117**:1775–1782.
- Weed HG, Ferguson ML, Gaff RL, Husted DS, Nelson JL, Voss AC. Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing

Acknowledgements

Authors thank Philippe Frank for helpful proofreading (Université de Tours, INSERM, N2C UMR 1069). The authors of this manuscript certify that they comply with the ethical guidelines for authorship and publishing in the *Journal of Cachexia, Sarcopenia and Muscle*.¹⁵⁹

Conflict of interest

The authors declare no conflict of interest.

Funding

This work was partly supported by the ‘Ligue Nationale Contre le Cancer’ (comités 22, 29, 37, 85), by the ‘Institut National du Cancer’ (PLBio), and by the ‘Canceropole Grand Ouest’ (CONCERTO, Régions Centre-Val de Loire and Pays de Loire et Bretagne). A.D. was supported by the Research French Ministry and the ‘Société Française de Nutrition Clinique et Métabolisme’ (SFNCM, Exceptional Research Prize).

- eicosapentaenoic acid. *Head Neck* 2011;**33**:1027–1033.
21. Cotogni P. Enteral versus parenteral nutrition in cancer patients: evidences and controversies. *Ann Palliat Med* 2016;**5**:42–49.
 22. Maddocks M, Jones LW, Wilcock A. Immunological and hormonal effects of exercise: implications for cancer cachexia. *Curr Opin Support Palliat Care* 2013;**7**:376–382.
 23. Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment—a systematic review. *Crit Rev Oncol Hematol* 2013;**88**:573–593.
 24. Oldervoll LM, Loge JH, Lydersen S, Paltiel H, Asp MB, Nygaard UV, et al. Physical exercise for cancer patients with advanced disease: a randomized controlled trial. *Oncologist* 2011;**16**:1649–1657.
 25. Reid J. Psychosocial, educational and communicative interventions for patients with cachexia and their family carers. *Curr Opin Support Palliat Care* 2014;**8**:334–338.
 26. Hudson P, Payne S. Family caregivers and palliative care: current status and agenda for the future. *J Palliat Med* 2011;**14**:864–869.
 27. Blum D, Stene GB, Solheim TS, Fayers P, Hjermstad MJ, Baracos VE, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model—A study based on data from an international multicentre project (EPCRC-CSA). *Ann Oncol* 2014;**25**:1635–1642.
 28. Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, et al. Diagnostic criteria for the classification of cancer-associated weight loss. *J Clin Oncol* 2015;**33**:90–99.
 29. Cederholm T, Bosaeus I, Barazzoni R, Bauer J, Van Gossum A, Klek S, et al. Diagnostic criteria for malnutrition—an ESPEN consensus statement. *Clin Nutr* 2015;**34**:335–340.
 30. van de Worp WRPH, Schols AMWJ, Dingemans A-MC, Op den Kamp CMH, Degens JHRJ, Kelders MCJM, et al. Identification of microRNAs in skeletal muscle associated with lung cancer cachexia. *J Cachexia Sarcopenia Muscle* 2020;**11**:452–463.
 31. Murton AJ, Maddocks M, Stephens FB, Marimuthu K, England R, Wilcock A. Consequences of late-stage non-small-cell lung cancer cachexia on muscle metabolic processes. *Clin Lung Cancer* 2017;**18**:e1–e11.
 32. Puig-Vilanova E, Rodriguez DA, Lloreta J, Ausin P, Pascual-Guardia S, Broquetas J, et al. Oxidative stress, redox signalling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. *Free Radic Biol Med* 2015;**79**:91–108.
 33. Bonetto A, Penna F, Aversa Z, Mercantini P, Baccino FM, Costelli P, et al. Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients. *Muscle Nerve* 2013;**48**:387–392.
 34. Aversa Z, Bonetto A, Penna F, Costelli P, Di Rienzo G, Lacitignola A, et al. Changes in myostatin signalling in non-weight-losing cancer patients. *Ann Surg Oncol* 2012;**19**:1350–1356.
 35. Gallagher IJ, Stephens NA, MacDonald AJ, Skipworth RJE, Husi H, Greig CA, et al. Suppression of skeletal muscle turnover in cancer cachexia: evidence from the transcriptome in sequential human muscle biopsies. *Clin Cancer Res* 2012;**18**:2817–2827.
 36. Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, Hesselink MK, et al. Pre-cachexia in patients with stages I–III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. *Lung Cancer* 2012;**76**:112–117.
 37. Smith IJ, Aversa Z, Hasselgren P-O, Pacelli F, Rosa F, Doglietto GB, et al. Calpain activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. *Muscle Nerve* 2011;**43**:410–414.
 38. Weber M-A, Krakowski-Roosen H, Schröder L, Kinscherf R, Krix M, Kopp-Schneider A, et al. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. *Acta Oncol* 2009;**48**:116–124.
 39. Ramamoorthy S, Donohue M, Buck M. Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. *Am J Physiol Endocrinol Metab* 2009;**297**:E392–E401.
 40. Busquets S, Deans C, Figueras M, Moore-Carrasco R, Lopez-Soriano F, Fearon K, et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. *Clin Nutr* 2007;**26**:614–618.
 41. Weber M-A, Kinscherf R, Krakowski-Roosen H, Aulmann M, Renk H, Künkele A, et al. Myoglobin plasma level related to muscle mass and fibre composition: a clinical marker of muscle wasting? *J Mol Med* 2007;**85**:887–896.
 42. Jagoe RT, Redfern CPF, Roberts RG, Gibson GJ, Goodship THJ. Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. *Clin Sci* 2002;**102**:353–361.
 43. Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. *Surgery* 1999;**126**:744–749, discussion 749–750.
 44. Banduseela V, Ochala J, Lamberg K, Kalimo H, Larsson L. Muscle paralysis and myosin loss in a patient with cancer cachexia. *Acta Myol* 2007;**26**:136–144.
 45. Judge SM, Nosacka RL, Delitto D, Gerber MH, Cameron ME, Trevino JG, et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. *JNCI Cancer Spectr* 2018;**2**:pky043.
 46. Zhang Y, Wang J, Wang X, Gao T, Tian H, Zhou D, et al. The autophagic-lysosomal and ubiquitin proteasome systems are simultaneously activated in the skeletal muscle of gastric cancer patients with cachexia. *Am J Clin Nutr* 2020;**111**:570–579.
 47. Ebhardt HA, Degen S, Tadini V, Schilb A, Johns N, Greig CA, et al. Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study. *J Cachexia Sarcopenia Muscle* 2017;**8**:567–582.
 48. Schmitt TL, Martignoni ME, Bachmann J, Fechtner K, Friess H, Kinscherf R, et al. Activity of the Akt-dependent anabolic and catabolic pathways in muscle and liver samples in cancer-related cachexia. *J Mol Med* 2007;**85**:647–654.
 49. Stephens NA, Skipworth RJE, Gallagher IJ, Greig CA, Guttridge DC, Ross JA, et al. Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients. *J Cachexia Sarcopenia Muscle* 2015;**6**:53–61.
 50. Skorokhod A, Bachmann J, Giese NA, Martignoni ME, Krakowski-Roosen H. Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia. *BMC Cancer* 2012;**12**:265.
 51. Johns N, Hatakeyama S, Stephens NA, Degen M, Degen S, Friauff W, et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. *PLoS ONE* 2014;**9**:e83618.
 52. Op den Kamp CM, Snepvangers FJ, de Theije CC, Schellekens JM, Laugs F, et al. Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. *Am J Clin Nutr* 2013;**98**:738–748.
 53. Taskin S, Stumpf VI, Bachmann J, Weber C, Martignoni ME, Friedrich O. Motor protein function in skeletal abdominal muscle of cachectic cancer patients. *J Cell Mol Med* 2014;**18**:69–79.
 54. Op den Kamp CM, Gosker HR, Lagarde S, Tan DY, Snepvangers FJ, Dingemans A-MC, et al. Preserved muscle oxidative metabolic phenotype in newly diagnosed non-small cell lung cancer cachexia. *J Cachexia Sarcopenia Muscle* 2015;**6**:164–173.
 55. de Castro GS, Simoes E, Lima JDCC, Ortiz-Silva M, Festuccia WT, Tokeshi F, et al. Human cachexia induces changes in mitochondria, autophagy and apoptosis in the skeletal muscle. *Cancer* 2019;**11**:1264.
 56. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. *Clin Nutr* 2008;**27**:793–799.
 57. Aversa Z, Pin F, Lucia S, Penna F, Verzaro R, Fazi M, et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. *Sci Rep* 2016;**6**:30340.
 58. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, Pacelli F, et al.

- Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. *Ann Surg* 2003;**237**:384–389.
59. Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. *Int J Biochem Cell Biol* 2005;**37**:2196–2206.
 60. Narasimhan A, Greiner R, Bathe OF, Baracos V, Damaraju S. Differentially expressed alternatively spliced genes in skeletal muscle from cancer patients with cachexia. *J Cachexia Sarcopenia Muscle* 2018;**9**:60–70.
 61. MacDonald AJ, Johns N, Stephens N, Greig C, Ross JA, Small AC, et al. Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. *Clin Cancer Res* 2015;**21**:1734–1740.
 62. D'Orlando C, Marzetti E, François S, Lorenzi M, Conti V, di Stasio E, et al. Gastric cancer does not affect the expression of atrophy-related genes in human skeletal muscle: muscle atrophy genes in cancer. *Muscle Nerve* 2014;**49**:528–533.
 63. Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB, Bossola M. Expression of NF-kappaB and I kappa B proteins in skeletal muscle of gastric cancer patients. *Eur J Cancer* 2010;**46**:191–197.
 64. Stephens NA, Gallagher IJ, Rooyackers O, Skipworth RJ, Tan BH, Marstrand T, et al. Using transcriptomics to identify and validate novel biomarkers of human skeletal muscle cancer cachexia. *Genome Med* 2010;**2**:1–2.
 65. Eley HL, Skipworth RJE, Deans DAC, Fearon KCH, Tisdale MJ. Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2 α may signal skeletal muscle atrophy in weight-losing cancer patients. *Br J Cancer* 2008;**98**:443–449.
 66. Bossola M, Muscaritoli M, Costelli P, Bellantone R, Pacelli F, Busquets S, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. *Am J Physiol Regul Integr Comp Physiol* 2001;**280**:R1518–R1523.
 67. Bossola M, Mirabella M, Ricci E, Costelli P, Pacelli F, Tortorelli AP, et al. Skeletal muscle apoptosis is not increased in gastric cancer patients with mild–moderate weight loss. *Int J Biochem Cell Biol* 2006;**38**:1561–1570.
 68. Stephens NA, Skipworth RJE, MacDonald AJ, Greig CA, Ross JA, Fearon KCH. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. *J Cachexia Sarcopenia Muscle* 2011;**2**:111–117.
 69. Johns N, Stretch C, Tan BHL, Solheim TS, Sørhaug S, Stephens NA, et al. New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss. *J Cachexia Sarcopenia Muscle* 2017;**8**:122–130.
 70. Narasimhan A, Ghosh S, Stretch C, Greiner R, Bathe OF, Baracos V, et al. Small RNAome profiling from human skeletal muscle: novel miRNAs and their targets associated with cancer cachexia. *J Cachexia Sarcopenia Muscle* 2017;**8**:405–416.
 71. Marzetti E, Lorenzi M, Landi F, Picca A, Rosa F, Tanganelli F, et al. Altered mitochondrial quality control signalling in muscle of old gastric cancer patients with cachexia. *Exp Gerontol* 2017;**87**:92–99.
 72. Collins P, Bing C, McCulloch P, Williams G. Muscle UCP-3 mRNA levels are elevated in weight loss associated with gastrointestinal adenocarcinoma in humans. *Br J Cancer* 2002;**86**:372–375.
 73. Brzezczńska J, Johns N, Schilb A, Degen S, Degen M, Langen R, et al. Loss of oxidative defense and potential blockade of satellite cell maturation in the skeletal muscle of patients with cancer but not in the healthy elderly. *Aging* 2016;**8**:1690–1702.
 74. Prokophuk O, Steinacker JM, Nitsche U, Otto S, Bachmann J, Schubert EC, et al. IL-4 mRNA is downregulated in the liver of pancreatic cancer patients suffering from cachexia. *Nutr Cancer* 2017;**69**:84–91.
 75. Ramage MJ, Johns N, Deans CDA, Ross JA, Preston T, Skipworth RJE, et al. The relationship between muscle protein content and CT-derived muscle radio-density in patients with upper GI cancer. *Clin Nutr* 2018;**37**:752–754.
 76. Sun Y-S, Ye Z-Y, Qian Z-Y, Xu X-D, Hu J-F. Expression of TRAF6 and ubiquitin mRNA in skeletal muscle of gastric cancer patients. *J Exp Clin Cancer Res CR* 2012;**31**:81.
 77. Talbert EE, Metzger GA, He WA, Guttridge DC. Modelling human cancer cachexia in colon 26 tumour-bearing adult mice. *J Cachexia Sarcopenia Muscle* 2014;**5**:321–328.
 78. Choi E, Carruthers K, Zhang L, Thomas N, Battaglino RA, Morse LR, et al. Concurrent muscle and bone deterioration in a murine model of cancer cachexia. *Physiol Rep* 2013;**1**:e00144.
 79. Sun R, Zhang S, Lu X, Hu W, Lou N, Zhao Y, et al. Comparative molecular analysis of early and late cancer cachexia-induced muscle wasting in mouse models. *Oncol Rep* 2016;**36**:3291–3302.
 80. Acharyya S, Butchbach MER, Sahenk Z, Wang H, Saji M, Carathers M, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. *Cancer Cell* 2005;**8**:421–432.
 81. Sandri M. Protein breakdown in cancer cachexia. *Semin Cell Dev Biol* 2016;**54**:11–19.
 82. Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP–ubiquitin–proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. *Am J Physiol* 1995;**268**:E996–E1006.
 83. Temparis S, Asensi M, Taillandier D, Arousseau E, Larbaud D, Obled A, et al. Increased ATP–ubiquitin-dependent proteolysis in skeletal muscles of tumour-bearing rats. *Cancer Res* 1994;**54**:5568–5573.
 84. Cai D, Frantz JD, Tawa NE, Melendez PA, Oh B-C, Lidov HGW, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. *Cell* 2004;**119**:285–298.
 85. Figueras M, Busquets S, Carbó N, Barreiro E, Almendro V, Argilés JM, et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. *FEBS Lett* 2004;**569**:201–206.
 86. Belizário JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. *Br J Cancer* 2001;**84**:1135–1140.
 87. Ishiko O, Sumi T, Yoshida H, Hyun Y, Ogita S. Expression of apoptosis regulatory proteins in the skeletal muscle of tumour-bearing rabbits compared with diet-restricted rabbits. *Int J Mol Med* 2001;**8**:279–283.
 88. Yoshida H, Ishiko O, Sumi T, Honda KI, Hirai K, Ogita S. Expression of apoptosis regulatory proteins in the skeletal muscle of tumour-bearing rabbits. *Jpn J Cancer Res Gann* 2001;**92**:631–637.
 89. Almasud AA, Giles KH, Miklavcic JJ, Martins KJB, Baracos VE, Putman CT, et al. Fish oil mitigates myosteatosis and improves chemotherapy efficacy in a pre-clinical model of colon cancer. *PLoS ONE* 2017;**12**:e0183576.
 90. Baracos VE, Mazurak VC, Bhullar AS. Cancer cachexia is defined by an ongoing loss of skeletal muscle mass. *Ann Palliat Med* 2019;**8**:3–12.
 91. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. *Acta Physiol* 2014;**210**:489–497.
 92. van Dijk DPJ, Bakens MJAM, Coolsen MME, Rensen SS, van Dam RM, Bours MJL, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. *J Cachexia Sarcopenia Muscle* 2017;**8**:317–326.
 93. Stretch C, Aubin J-M, Mickiewicz B, Leugner D, Al-Manasra T, Tobola E, et al. Sarcopenia and myosteatosis are accompanied by distinct biological profiles in patients with pancreatic and periampullary adenocarcinomas. *PLoS ONE* 2018;**13**:e0196235.
 94. Mukai R, Matsui N, Fujikura Y, Matsumoto N, Hou D-X, Kanzaki N, et al. Preventive effect of dietary quercetin on disuse muscle atrophy by targeting mitochondria in denervated mice. *J Nutr Biochem* 2016;**31**:67–76.
 95. Kang C, Yeo D, Ji LL. Muscle immobilization activates mitophagy and disrupts mitochondrial dynamics in mice. *Acta Physiol* 2016;**218**:188–197.
 96. Fontes-Oliveira CC, Busquets S, Toledo M, Penna F, Paz Aylwin M, Sirisi S, et al. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered

- energetic efficiency? *Biochim Biophys Acta* 2013;**1830**:2770–2778.
97. Shum AMY, Mahendradatta T, Taylor RJ, Painter AB, Moore MM, Tsoli M, et al. Disruption of MEF2C signalling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. *Aging* 2012;**4**:133–143.
 98. White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, Carson JA. Muscle oxidative capacity during IL-6-dependent cancer cachexia. *Am J Physiol Regul Integr Comp Physiol* 2011;**300**:R201–R211.
 99. Feroselle C, García-Arumí E, Puig-Vilanova E, Andreu AL, Urtreger AJ, de Kier Joffé EDB, et al. Mitochondrial dysfunction and therapeutic approaches in respiratory and limb muscles of cancer cachectic mice. *Exp Physiol* 2013;**98**:1349–1365.
 100. Padrão AI, Oliveira P, Vitorino R, Colaço B, Pires MJ, Márquez M, et al. Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria plasticity. *Int J Biochem Cell Biol* 2013;**45**:1399–1409.
 101. Julienne CM, Damas J-F, Goupille C, Pinault M, Berri C, Collin A, et al. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. *J Cachexia Sarcopenia Muscle* 2012;**3**:265–275.
 102. Busquets S, Almendro V, Barreiro E, Figueras M, Argilés JM, López-Soriano FJ. Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake: involvement of ROS in a model of mouse cancer cachexia. *FEBS Lett* 2005;**579**:717–722.
 103. Bing C, Brown M, King P, Collins P, Tisdale MJ, Williams G. Increased gene expression of brown fat uncoupling protein (UCP)1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia. *Cancer Res* 2000;**60**:2405–2410.
 104. Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, Perry RA, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice. *J Cachexia Sarcopenia Muscle* 2017;**8**:926–938.
 105. Roeland EJ, Ma JD, Nelson SH, Seibert T, Heavey S, Revta C, et al. Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials. *Support Care Cancer* 2017;**25**:365–369.
 106. Blauwhoff-Buskermolten S, Langius JAE, Becker A, Verheul HMW, de van der Schueren MAE. The influence of different muscle mass measurements on the diagnosis of cancer cachexia. *J Cachexia Sarcopenia Muscle* 2017;**8**:615–622.
 107. Zhou T, Wang B, Liu H, Yang K, Thapa S, Zhang H, et al. Development and validation of a clinically applicable score to classify cachexia stages in advanced cancer patients. *J Cachexia Sarcopenia Muscle* 2018;**9**:306–314.
 108. Anoveros-Barrera A, Bhullar AS, Stretch C, Esfandiari N, Dunichand-Hoedl AR, Martins KJB, et al. Clinical and biological characterization of skeletal muscle tissue biopsies of surgical cancer patients. *J Cachexia Sarcopenia Muscle* 2019;**10**:1356–1377.
 109. Montalvo RN, Counts BR, Carson JA. Understanding sex differences in the regulation of cancer-induced muscle wasting. *Curr Opin Support Palliat Care* 2018;**12**:394–403.
 110. Yoon SL, Grundmann O, Williams JJ, Gordan L, George TJ. Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: results from a pilot study. *Cancer Med* 2018;**7**:3695–3703.
 111. Agustsson T, Wikrantz P, Rydén M, Brismar T, Isaksson B. Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia. *Nutrition* 2012;**28**:851–855.
 112. Kim HJ, Kim HJ, Yun J, Kim KH, Kim SH, Lee S-C, et al. Pathophysiological role of hormones and cytokines in cancer cachexia. *J Korean Med Sci* 2012;**27**:128–134.
 113. Lerner L, Tao J, Liu Q, Nicoletti R, Feng B, Krieger B, et al. MAP3K11/GDF15 axis is a critical driver of cancer cachexia. *J Cachexia Sarcopenia Muscle* 2016;**7**:467–482.
 114. Penafuerte CA, Gagnon B, Sirois J, Murphy J, MacDonald N, Tremblay ML. Identification of neutrophil-derived proteases and angiotensin II as biomarkers of cancer cachexia. *Br J Cancer* 2016;**114**:680–687.
 115. Loumays A, de Barys M, Nachit M, Lause P, Frateur L, van Maanen A, et al. Role of activin A and myostatin in human cancer cachexia. *J Clin Endocrinol Metab* 2015;**100**:2030–2038.
 116. Batista ML, Oliván M, Alcantara PSM, Sandoval R, Peres SB, Neves RX, et al. Adipose tissue-derived factors as potential biomarkers in cachectic cancer patients. *Cytokine* 2013;**61**:532–539.
 117. Burney BO, Hayes TG, Smiechowska J, Cardwell G, Papusha V, Bhargava P, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. *J Clin Endocrinol Metab* 2012;**97**:E700–E709.
 118. Felix K, Fakelman F, Hartmann D, Giese NA, Gaida MM, Schnölzer M, et al. Identification of serum proteins involved in pancreatic cancer cachexia. *Life Sci* 2011;**88**:218–225.
 119. Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, et al. Adipokines and ghrelin in gastric cancer cachexia. *World J Gastroenterol* 2008;**14**:3633–3641.
 120. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Kustrzeba-Wojcicka I, et al. Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF- α , VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients. *Clin Biochem* 2007;**40**:1353–1360.
 121. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KCH. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor: cachectic factor in pancreatic cancer. *Br J Surg* 2000;**87**:53–58.
 122. Loumays A, Thissen J-P. Biomarkers of cancer cachexia. *Clin Biochem* 2017;**50**:1281–1288.
 123. Bilir C, Engin H, Can M, Temi YB, Demirtas D. The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia. *Med Oncol* 2015;**32**:56.
 124. Hong N, Yoon H, Lee Y, Kim HR, Lee BW, Rhee Y, et al. Serum PTHrP predicts weight loss in cancer patients independent of hypercalcemia, inflammation, and tumour burden. *J Clin Endocrinol Metab* 2016;**101**:1207–1214.
 125. Fujiwara Y, Kobayashi T, Chayahara N, Imamura Y, Toyoda M, Kiyota N, et al. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. *PLoS ONE* 2014;**9**:e113259.
 126. Lung T, Matozan K, Risch M, Sakem B, Nydegger UE, Risch L. Complement systems C4, C3 and CH50 not subject to a circadian rhythm. *Diagnosi* 2018;**5**:77–82.
 127. Wright KP, Drake AL, Frey DJ, Fleschner M, Desouza CA, Gronfier C, et al. Influence of sleep deprivation and circadian misalignment on cortisol, inflammatory markers, and cytokine balance. *Brain Behav Immun* 2015;**47**:24–34.
 128. Manole E, Ceafalan LC, Popescu BO, Dumitru C, Bastian AE. Myokines as possible therapeutic targets in cancer cachexia. *J Immunol Res* 2018;**2018**:e8260742.
 129. Petruzzelli M, Wagner EF. Mechanisms of metabolic dysfunction in cancer-associated cachexia. *Genes Dev* 2016;**30**:489–501.
 130. Tomasin R, Martin ACBM, Cominetti MR. Metastasis and cachexia: alongside in clinics, but not so in animal models. *J Cachexia Sarcopenia Muscle* 2019;**10**:1183–1194.
 131. Roy A, Kumar A. ER stress and unfolded protein response in cancer cachexia. *Cancer* 2019;**11**:1929.
 132. Bohnert KR, Gallot YS, Sato S, Xiong G, Hindi SM, Kumar A. Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia. *FASEB J* 2016;**30**:3053–3068.
 133. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. *Nat Rev Cancer* 2014;**14**:581–597.
 134. Wu J, Kaufman RJ. From acute ER stress to physiological roles of the unfolded protein response. *Cell Death Differ* 2006;**13**:374–384.
 135. Barreiro E, Salazar-Degracia A, Sancho-Muñoz A, Gea J. Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases. *J Cell Physiol* 2019;**234**:11315–11329.

136. Chaurasia B, Summers SA. Ceramides—lipotoxic inducers of metabolic disorders. *Trends Endocrinol Metab* 2015;**26**:538–550.
137. Pathinayake PS, Hsu AC-Y, Waters DW, Hansbro PM, Wood LG, Wark PAB. Understanding the unfolded protein response in the pathogenesis of asthma. *Front Immunol* 2018;**9**:175.
138. Vance JE. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. *Biochim Biophys Acta BBA - Mol Cell Biol Lipids* 2014;**1841**:595–609.
139. Fujimoto M, Hayashi T. New insights into the role of mitochondria-associated endoplasmic reticulum membrane. *Int Rev Cell Mol Biol* 2011;**292**:73–117.
140. Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. *Arch Med Sci* 2017;**13**:851–863.
141. Braun N, Gomes F, Schütz P. 'The obesity paradox' in disease—is the protective effect of obesity true? *Swiss Med Wkly* 2015;**145**:w14265.
142. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. *Proc Nutr Soc* 2016;**75**:188–198.
143. Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. *Science* 2011;**333**:233–238.
144. Fouladiun M, Körner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. *Cancer* 2005;**103**:2189–2198.
145. Leal V de O, Mafrá D. Adipokines in obesity. *Clin Chim Acta* 2013;**419**:87–94.
146. Nicholson T, Church C, Baker DJ, Jones SW. The role of adipokines in skeletal muscle inflammation and insulin sensitivity. *J Inflamm Lond Engl* 2018;**15**.
147. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. *ISRN Inflamm* 2013;**2013**:139239.
148. Han J, Meng Q, Shen L, Wu G. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. *Lipids Health Dis* 2018;**17**:14.
149. Argilés JM, López-Soriano FJ, Busquets S. Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. *Drug Discov Today* 2009;**14**:208–213.
150. Argilés JM, López-Soriano J, Almendro V, Busquets S, López-Soriano FJ. Cross-talk between skeletal muscle and adipose tissue: a link with obesity? *Med Res Rev* 2005;**25**:49–65.
151. Arner P, Langin D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. *Trends Endocrinol Metab* 2014;**25**:255–262.
152. Potes Y, de Luxán-Delgado B, Rodríguez-González S, Guimarães MRM, Solano JJ, Fernández-Fernández M, et al. Overweight in elderly people induces impaired autophagy in skeletal muscle. *Free Radic Biol Med* 2017;**110**:31–41.
153. Argilés JM, Stemmler B, López-Soriano FJ, Busquets S. Nonmuscle tissues contribution to cancer cachexia. *Mediators Inflamm* 2015;**2015**:182872.
154. Regan JN, Trivedi T, Guise TA, Waning DL. The role of TGFβ in bone–muscle crosstalk. *Curr Osteoporos Rep* 2017;**15**:18–23.
155. Herremans KM, Riner AN, Cameron ME, Trevino JG. The microbiota and cancer cachexia. *Int J Mol Sci* 2019;**20**:6267.
156. Cai D, Liu T. Hypothalamic inflammation: a double-edged sword to nutritional diseases. *Ann N Y Acad Sci* 2011;**1243**:E1–E39.
157. Molino A, Iannace A, Colaiacomo MC, Farcomeni A, Emiliani A, Gualdi G, et al. Cancer anorexia: hypothalamic activity and its association with inflammation and appetite-regulating peptides in lung cancer. *J Cachexia Sarcopenia Muscle* 2017;**8**:40–47.
158. Bodine SC, Furlow JD. Glucocorticoids and skeletal muscle. *Adv Exp Med Biol* 2015;**872**:145–176.
159. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the *Journal of Cachexia, Sarcopenia and Muscle*: update 2019. *J Cachexia Sarcopenia Muscle* 2019;**10**:1143–1145.